Kodak Establishes Pharmaceutical Unit To Tackle Shortages
US Development Bank Signs $765m Loan For Kodak
Kodak’s new pharmaceutical unit receives a $765m loan from the US International Development Finance Corporation, through President Trump’s Defense Production Act, to produce critical pharma components that are essential but have lapsed into chronic national shortage, as defined by the FDA.
You may also be interested in...
The Trump administration’s move to strengthen domestic manufacture of essential medicines raises a lot of questions – and industry’s ire.
US start-up Phlow has been awarded federal government funding of $354m as part of a contract to manufacture essential medicines in the US amid the COVID-19 pandemic, in partnership with AMPAC Fine Chemicals and Civica Rx.
In an attempt to strengthen the US generic drug supply chain and reduce dependence on certain countries for supply, the AAM has proposed a policy framework “blueprint” that requires government purchasing commitments in exchange for industry manufacturing expansion.